Cryotherapy for Post-Hemorrhoidectomy Pain
NCT07714122
Cardiovascular Diseases, Digestive System Diseases
Cairo, Al-Manial, Cairo, Egypt, Egypt
View Trial DetailsNCT Number: NCT07719881
This observational multicenter study aims to develop and validate the Hemorrhoidectomy Quality Assessment Scale (HeQAS), a histopathological tool designed to assess the technical quality of excisional hemorrhoidectomy. The project includes a methodological validation phase using blinded assessment of surgical specimens by expert pathologists, followed by a clinical cohort phase comparing micro-open excisional hemorrhoidectomy (microOEH) and conventional open excisional hemorrhoidectomy (OEH) in real-world practice. The study will evaluate the reproducibility and applicability of HeQAS and explore whether microOEH is associated with lower histological tissue damage than conventional OEH.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Observational
Hospital Son Llatzer, Palma de Mallorca, Balearic Islands, Spain
Excisional hemorrhoidectomy remains the standard surgical treatment for advanced hemorrhoidal disease, but there is currently no validated histopathological tool to objectively assess the technical quality of tissue resection. This project aims to develop and validate the Hemorrhoidectomy Quality Assessment Scale (HeQAS), a structured histopathological score designed to evaluate technical quality in excisional hemorrhoidectomy specimens, and then to apply the validated instrument in a real-world comparative clinical setting.
The project is organized into two predefined and sequential components. Study 1 is a multicenter, ambispective, cross-sectional methodological validation study designed to develop, refine, and validate the HeQAS instrument. In this phase, a pilot set of 10 retrospective hemorrhoidectomy specimens will be used to refine item definitions, improve applicability, and create a reference atlas. Afterwards, a validation set of 40 ambispective specimens will be assessed independently and blindly by pathologists from participating centers. The main purpose of this phase is to determine the reproducibility and reliability of the score through inter-observer agreement, intra-observer agreement, and internal consistency analyses. Only specimens with adequate histological quality will be included, and all slides will be pseudonymized and centrally reviewed without access to clinical, surgical, or demographic information.
Study 2 is a multicenter, observational, analytical cohort study performed in routine clinical practice. This phase will include patients undergoing either micro-open excisional hemorrhoidectomy (microOEH) or conventional open excisional hemorrhoidectomy (OEH), with ambispective recruitment of retrospective and prospective cases not previously used in Study 1. A total of 80 patients are planned, with 40 cases in the microOEH group and 40 cases in the conventional OEH group. Surgical indication, operative technique, and postoperative management will not be modified by the study and will remain entirely based on usual clinical practice and physician judgment.
In Study 2, all surgical specimens will undergo standardized histopathological processing according to the protocol established during the validation phase and will be evaluated centrally and blindly using the HeQAS instrument. The primary comparative objective is to assess differences in HeQAS total score between microOEH and conventional OEH, as a measure of tissue resection quality and histological tissue damage. Secondary analyses will explore associations between HeQAS scores and relevant clinical outcomes, including postoperative pain, early and late complications, and clinical failure rate at 12 months. Additional analyses will evaluate potential differences between retrospective and prospective cases and adjust for relevant confounding factors such as age, sex, hemorrhoidal grade, surgeon experience, and center.
The study is observational and non-interventional. It does not assign treatment, alter surgical indications, require additional invasive procedures, or impose visits beyond standard care. Histopathological material and clinical data are obtained as part of routine clinical management, and the research procedures are limited to standardized specimen processing, blinded pathological assessment, and collection of routinely generated clinical data. Overall, the project is intended to provide a reproducible histopathological quality assessment tool for excisional hemorrhoidectomy and to determine whether microOEH is associated with less histological tissue damage than conventional OEH in real-world practice.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Availability of the surgical specimen with adequate histopathological preservation for standardized processing and HeQAS assessment.
Availability of routine clinical follow-up data required for outcome assessment (pain, complications, and 12-month clinical status).
Exclusion criteria
Surgical specimens with inadequate fixation, autolysis, or fragmentation that preclude reliable histopathological assessment according to the protocol.
Incidental diagnosis of malignancy (carcinoma) in the surgical specimen.
Intraoperative change of surgical technique that prevents clear assignment to one cohort (micro-open excisional hemorrhoidectomy or conventional open excisional hemorrhoidectomy).
Prior use of the same specimen in the methodological validation study (Study 1) of HeQAS.
-
Time frame: At the time of histopathological assessment of the surgical specimen (within routine pathology processing after surgery).
Total score of the Hemorrhoidectomy Quality Assessment Scale (HeQAS), a composite histopathological measure of technical quality of excisional hemorrhoidectomy specimens, calculated from predefined items related to specimen size, muscle involvement at the margin and deep surface, depth and extent of thermal injury, and distance from the deepest hemorrhoidal vessels to the resection margin. Higher scores indicate greater histological tissue damage and lower technical quality.
Time frame: 7 days after surgery
Patient-reported postoperative pain intensity at day 7 after surgery, measured using a 0-10 visual analogue scale (VAS) for pain at rest and/or after defecation, recorded from routine clinical follow-up data.
Protocolo-proyecto-definicion-y-validacion-de-HeQAS-para-evaluar-la-calidad-tecnica-de-la-hemor.docx
Time frame: Within 30 days after surgery
Occurrence and severity of early postoperative complications within 30 days after surgery, classified according to the Clavien-Dindo system and summarized using the Comprehensive Complication Index (CCI), based on routinely collected clinical data.
Time frame: 12 months after surgery
Proportion of patients meeting predefined criteria for clinical failure of the hemorrhoidectomy technique at 12 months of follow-up, according to the clinical failure rate (CFR) definition used in the protocol (persistent or recurrent symptoms requiring additional treatment).
Time frame: 15 days after surgery
Total number of analgesic doses taken during the first 15 days after surgery, recorded from routine postoperative follow-up data.
Time frame: a year after surgery
Continence status assessed using the Wexner incontinence score during postoperative follow-up.
Hospital Son Llatzer
Other
Definition and Validation of the Hemorrhoidectomy Quality Assessment Score (HeQAS) to Evaluate the Technical Quality of Excisional Hemorrhoidectomy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07714122
Cardiovascular Diseases, Digestive System Diseases
Cairo, Al-Manial, Cairo, Egypt, Egypt
View Trial DetailsNCT07587892
Cardiovascular Diseases, Digestive System Diseases
Moscow, Russia
View Trial DetailsNCT06884774
Cardiovascular Diseases, Digestive System Diseases
Minya, Egypt
View Trial DetailsNCT07171294
Hemorrhoidectomy, Minimal Invasive Surgery
Palma, Spain
View Trial Details